RxDoctor Payments Data

Mohamad Hadidi, MD

Neurology · Clarksdale, MSNPI 1164460101

Payments from drug & device makers

$1,518in general payments, 2019–2025

Across 68 payments — averaging $22.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$194
  • Teva Pharmaceuticals USA, Inc.$193
  • Eisai Inc.$179
  • AstraZeneca$145
  • Sunovion Pharmaceuticals Inc.$114
  • Amgen$112
  • plus $580 from 11 others

What the payments were for

  • Speaking & faculty fees$1117%
  • Food & beverage$1,39392%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,518 in reported general payments places this provider in the 45th percentile of 111 neurology providers in Mississippi.

See all neurology providers in Mississippi

Medicare billing

Part B allowed, 2024
$131,397
Medicare patients
356
Services billed
1,010

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AptiomEslicarbazepine Acetate84$187,223
IngrezzaValbenazine Tosylate22$178,554
FycompaPerampanel110$116,413
TecfideraDimethyl Fumarate12$111,521
NuplazidPimavanserin Tartrate15$109,508
XcopriCenobamate86$79,100
BriviactBrivaracetam32$42,673
Lamictal XrLamotrigine12$32,471
XareltoRivaroxaban25$20,408
Keppra XrLevetiracetam12$16,479
Lacosamide124$15,025
Lamotrigine ErLamotrigine29$11,638
RytaryCarbidopa/Levodopa16$10,896
LamictalLamotrigine29$10,308
Levetiracetam185$7,649

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sunovion Pharmaceuticals Inc.Aptiom$114$187,22384 claims
Neurocrine Biosciences, Inc.Ingrezza$96$178,55422 claims
Eisai Inc.Fycompa$179$116,413110 claims
BiogenTecfidera$42$111,52112 claims
SK Life Science, Inc.Xcopri$194$79,10086 claims
UCB, Inc.Briviact$24$42,67332 claims
Amneal Pharmaceuticals LLCRytary$111$10,89616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 111 neurology providers in Mississippi.

Other neurology in Clarksdale

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →